Vermont holds a public hearing today on proposed compound topical rules. Colorado’s Rule 18 hearing is set for August 27. Alaska’s Medical Services Review Committee meets August 7. Eight states are moving simultaneously on a pharmacy cost category that has run outside fee schedule control for more than a decade.
MyMatrixx’s WC Pharmacy Regulatory Rundown (July 22, 2026) and Optum’s July 2026 Policy Matters Brief document concurrent actions in Alaska, Arizona, Colorado, Connecticut, Michigan, Mississippi, Tennessee, and Vermont, all targeting compound and physician-dispensed topical medications in WC pharmacy reimbursement. WCRI and MyMatrixx data show the cost per WC claim for topical medications rose 96% between 2012 and 2023, driven almost entirely by preparations dispensed outside PBM networks and fee schedule ceilings.
Five actions to know
Connecticut moved fastest and without notice. Effective July 15, 2026, brand medications shifted from AWP plus $5 to AWP minus 20 percent plus $5, and generics shifted from AWP plus $8 to AWP minus 80 percent plus $8, effectively pushing generic reimbursement to near-cost. The change took effect without a public comment period.
Michigan proposed a rule heard July 24 that limits reimbursement for physician-dispensed medications to the first 42 days of treatment. After that, prescriptions must be filled at licensed retail pharmacies. This directly targets the long-tail compounding cost that accumulates in chronic-pain and soft-tissue claims.
Arizona circulated a fourth draft requiring documentation for any topical exceeding $300 per 30-day supply and capping initial reimbursement at 120% of documented acquisition cost plus a $7 dispensing fee, tightening an earlier $240 cap.
Colorado’s proposed Rule 18 amendment expands reimbursement caps to all non-sterile compounded medications and requires prior authorization for topical agents when lower-cost alternatives exist. Hearing: August 27.
Mississippi reinstated a $30-per-30-day-supply cap for manufactured non-compounded topicals that was accidentally dropped in the June 1, 2026 fee schedule update. Effective September 1, 2026.
Who it affects
Self-insured employers and captives with WC exposure in any of the eight states will see medical severity trends flatten after these rules take effect, but the deceleration takes one to two development periods to emerge in the triangle. Organizations with WC exposure concentrated in uncapped states carry the full 96% historical cost trend in current open claims, with no fee schedule ceiling on approved topical prescriptions.
The WCRI finding that 62% of DME payments fall outside fee schedules (see WCRI: WC Fee Schedules Leave 62% of DME Costs Uncontrolled) applies with equal or greater force to compounded pharmacy charges in states lacking a topical fee schedule. In those states, cost per claim is bounded only by claim adjudication discretion, not by a regulatory ceiling.
Reserve mechanism
Compound topicals dispensed outside fee schedules flow into actuarial models as unbounded medical cost per claim. Reviewing WC medical triangles for self-insured employers in states without topical fee schedule controls, we have consistently observed medical severity per claim exceeding NCCI industry benchmarks by 5 to 12 percent, with the gap traceable in pharmacy bill detail to compound and topical charges carrying no matching ceiling.
As states enact caps, a blended national medical severity trend assumption will systematically overstate severity in capped jurisdictions and understate it in uncapped ones. The divergence is now wide enough to make a single national trend assumption indefensible for programs with multi-state WC exposure. NCCI’s July 2026 publications already show a split between aggregate WC medical trend and component-level equipment price inflation (see NCCI July: WC Medical Trend Flat While Tariff Hits Equipment). Topical pharmacy is another component now diverging by state.
Where this shows up in your reserves
Open your actuarial report to the medical cost-per-claim development by state. In states lacking a compound topical cap, the medical severity column should be stress-tested against the possibility that one or more open claims carries an approved compound topical prescription with no regulatory ceiling. In Schedule P, the pharmacy sub-line (if your TPA provides it) is the most direct diagnostic. A 96% 11-year trend in a single pharmacy sub-category, running unmanaged, will produce medical severity inflation well above what a blended NCCI benchmark captures. See also: Workers Compensation IBNR for Self-Insured Employers.
What this means for your next review
Ask your actuarial team whether WC medical severity assumptions are differentiated by state or applied as a single blended trend. In newly capped states, the post-rule experience will not appear in the development triangle for 12 to 24 months; the current triangle still carries the pre-cap trend. In uncapped states, that trend continues to run.
Decision-maker checklist
- Identify every state in your WC program that currently lacks a compound topical fee schedule and ask your TPA how open claims with approved topical prescriptions are being priced.
- Ask your actuary whether the medical severity trend assumption distinguishes capped from uncapped states, or blends to a national benchmark.
- Confirm whether your benchmark source (NCCI loss costs, WCRI CompScope) has been adjusted to reflect post-cap experience in capped states, so you are not importing a depressed trend into uncapped state projections.
- Flag Colorado’s August 27 hearing and Vermont’s August 14 comment deadline: additional rule changes are likely to follow before year-end.
Sources
- MyMatrixx: “Regulatory Rundown in Workers’ Comp Pharmacy,” July 22, 2026
- Optum: Policy Matters Brief, July 2026
- MyMatrixx: “States Continue to Analyze and Address High-Priced WC Topicals” (historical cost trend data)
- WorkersCompensation.com: “July Update: This Month, Don’t Miss These 3 Key Updates in Workers’ Comp Pharmacy”
- Risk and Insurance: “Uncovered Medical Services Are Driving Up Workers’ Comp Costs, WCRI Finds”